Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVALT-17: Erlotinib versus intercalated erlotinib with cisplatin + pemetrexed in first-line EGFR-mutated advanced NSCLC
NL-OMON45179Phase 3Active, not recruiting
- Sponsor
- NVALT
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Erlotinib monotherapy with Cisplatin + pemetrexed + intercalated erlotinib (2 arms). Primary endpoint: Progression-free survival. Started May 2014; status: active, not recruiting.
02
Drugs
erlotinibcisplatinpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON45179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45179.